Macular Therapeutics

Macular Therapeutics is a private ophthalmology-focused biotechnology company developing botulinum-based neuromodulator therapies for macular degeneration and other serious retinal diseases. The company is centered on a non-intravitreal delivery approach intended to affect tissues at the back of the eye while potentially improving tolerability versus direct intraocular injections. Its publicly described strategy combines neuromodulation and tissue remodeling concepts to stabilize cellular barriers and retinal structures. Macular Therapeutics has highlighted patent protection around methods for treating dry macular degeneration, slowing disease progression, and enhancing anti-VEGF effects on intraretinal edema. The company appears to be an early clinical-stage/private biotech rather than a commercial-stage ophthalmology company.